Download PDF
Thromb Haemost 2009; 101(06): 1041-1043
DOI: 10.1160/TH09-02-0078
Viewpoint Article
Schattauer GmbH

Future of oral antiplatelet therapy: Four challenged hypotheses

Victor L. Serebruany
1   HeartDrug™ Research Laboratories, Johns Hopkins University, Towson, Maryland, USA
,
Leonid M. Makarov
1   HeartDrug™ Research Laboratories, Johns Hopkins University, Towson, Maryland, USA
› Author Affiliations
Further Information

Publication History

Received: 04 February 2009

Accepted after major revision: 18 March 2009

Publication Date:
24 November 2017 (online)

    Permissions and Reprints

 

 

  • References

  • 1 Diener HC, Bogousslavsky J, Brass LM. et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet 2004; 364: 331-337.
    CrossrefPubMedGoogle Scholar
  • 2 Bhatt DL, Fox KA, Hacke W. et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006; 354: 1706-1717.
    CrossrefPubMedGoogle Scholar
  • 3 Sacco RL, Diener HC, Yusuf S. et al. PRoFESS Study Group.. Aspirin and extended-release dipyrida-mole versus clopidogrel for recurrent stroke. N Engl J Med 2008; 359: 1238-1251.
    CrossrefPubMedGoogle Scholar
  • 4 Wiviott SD, Braunwald E, McCabe CH. et al. the TRITON-TIMI 38 Investigators.. Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes. N Engl J Med 2007; 357: 2001-2015.
    CrossrefPubMedGoogle Scholar
  • 5 Serebruany VL. The “clopidogrel resistance” trap. Am J Cardiol 2007; 100: 1044-1046.
    CrossrefPubMedGoogle Scholar
  • 6 Lansky AJ, Tsuchiya Y, Brener M. et al. Comparison between ticlopidine and clopidogrel in patients undergoing primary stenting in acute myocardial infarction: Results from the CADILLAC trial. Catheter Cardiovasc Interv 2008; 72: 917-924.
    CrossrefPubMedGoogle Scholar
  • 7 Berger JS, Frye CB, Harshaw Q. et al. Impact of clopidogrel in patients with acute coronary syndromes requiring coronary artery bypass surgery: a multicenter analysis. J Am Coll Cardiol 2008; 52: 1693-1701.
    CrossrefPubMedGoogle Scholar
  • 8 Serebruany VL, Atar D. Assessment of bleeding events in clinical trials – proposal of a new classification. Am J Cardiol 2007; 99: 288-290.
    CrossrefPubMedGoogle Scholar
  • 9 Cohen M, Diez JE, Levine GN. et al. ACC; AHA.. Pharmacoinvasive management of acute coronary syndrome: incorporating the 2007 ACC/AHA guidelines: the CATH (cardiac catheterization and antithrombotic therapy in the hospital) Clinical Consensus Panel Report--III. J Invasive Cardiol 2007; 19: 525-538.
    PubMedGoogle Scholar
  • 10 Silber S, Richartz BM, Brilmayer M. The European Society of Cardiology (ESC). The European Society of Cardiology (ESC) guidelines for percutaneous coronary interventions (PCI). Herz 2006; 31: 836-846.
    CrossrefPubMedGoogle Scholar
  • 11 Antman EM, Wiviott SD, Murphy SA. et al. Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolysis In Myocardial Infarction) analysis. J Am Coll Cardiol 2008; 51: 2028-2033.
    CrossrefPubMedGoogle Scholar
  • 12 Serebruany VL. Aggressive antiplatelet strategies: time to reconsider. Eur Heart J 2007; 28: 2183-2184.
    CrossrefPubMedGoogle Scholar
  • 13 Wiviott SD, Antman EM, Gibson CM. et al. TRITON-TIMI 38 Investigators.. Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38). Am Heart J 2006; 152: 627-635.
    CrossrefPubMedGoogle Scholar
  • 14 Wiviott SD, Antman EM, Winters KJ. et al. JUMBO-TIMI 26 Investigators.. Randomized comparison of prasugrel a novel thienopyridine P2Y(12) antagonist with clopidogrel in percutaneous coronary intervention. Circulation 2005; 111: 3366-3373.
    CrossrefPubMedGoogle Scholar
  • 15 Kaul S, Shah K, Diamond JA. Validity of the combined efficacy plus safety composite endpoint (Net Clinical Benefit) in TRITON-TIMI 38. Circulation 2008; 118: S819.
    PubMedGoogle Scholar
  • 16 Rao AK, Pratt C, Berke A. et al. Thrombolysis in Myocardial Infarction (TIMI) Trial--phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol 1988; 11: 1-11.
    CrossrefPubMedGoogle Scholar
  • 17 Serebruany VL. Platelet inhibition with prasugrel and increased cancer risks: Potential causes and implications. Am J Med 2009; 122: 407-408.
    CrossrefPubMedGoogle Scholar
  • 18 Serebruany VL, Midei MG, Meilman H. et al. Platelet inhibition with prasugrel (CS-747) compared with clopidogrel in patients undergoing coronary stenting: the subset from the JUMBO study. Postgrad Med J 2006; 82: 404-410.
    CrossrefPubMedGoogle Scholar
  • 19 Serebruany VL, Midei MG, Malinin AI. et al. Absence of interaction between atorvastatin and clopidogrel in prospective data: The Interaction of Atorvastatin and Clopidogrel (INTERACTION Study). Arch Int Med 2004; 164: 2051-2057.
    CrossrefPubMedGoogle Scholar
  • 20 Angiolillo DJ. ADP receptor antagonism: what’s in the pipeline?. Am J Cardiovasc Drugs 2007; 7: 423-432.
    CrossrefPubMedGoogle Scholar